Influence of hepatic impairment on the pharmacokineticsand pharmacodynamics of the P2Y12 receptor antagonist selatogrel

First published in Clinical and Translational Science on 2022 Aug.
Clin Transl Sci. 2022 Aug;15(8):1906-1915. doi: 10.1111/cts.13298. Epub 2022 May 18

Authors: Schilling U, Hsin CH, Delahaye S, Krause A, Wuelfrath H, Halabi A, Dingemanse J.

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board
located at CRS Mannheim

LET’S TALK SCIENCE

+49 621 150 45 – 0

Dr. Marc Hetzel

VP & Head of Business Development
located at CRS Management

LET’S TALK BUSINESS

+49 621 150 45 – 0

Influence of hepatic impairment on the pharmacokineticsand pharmacodynamics of the P2Y12 receptor antagonist selatogrel

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.

Midazolam microdosing applied in early clinical development for drug-drug interaction assessment.

The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.